Malignant Peritoneal Mesothelioma Masquerades as Peritoneal Metastasis on 18F-FDG PET/CT Scans; a Rare Diagnosis that Should Not Be Missed

Claimon, Apichaya; Bang, Ji In; Cheon, Gi Jeong; Kim, Euishin Edmund; Lee, Dong Hoon

doi:10.1007/s13139-015-0360-2

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Magnetic resonance imaging and positron emission tomography provide little additional information, and their roles in evaluating MPM remain unclear. 17,18 In addition to imaging elevated cancer antigen (CA)-125; however, this marker alone is not tumor specific, and it is typically best used to monitor for disease recurrence or progression in those with a confirmed diagnosis. 19 The currently accepted approach for initial MPM treatment is cytoreductive surgery (CRS) and regional chemotherapy treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Malignant Peritoneal Mesothelioma: A Tertiary Center Experience

Şahin¹

2018

UHOD

View full text Add to dashboard Cite

In this study, we aimed to investigate the effect of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HI-PEC) procedures on overall survival (OS), morbidity, and mortality rates in patients with malignant peritoneal mesothelioma (MPM), an extremely rare tumor. Between January 2012 and March 2017, 21 patients who were diagnosed with a MPM and underwent CRS plus HIPEC were retrospectively analyzed. The median age was 60 (range, 18 to 80) years. Eighteen patients (76.2%) had a history of exposure to asbestos. The median follow-up was 17 months (range, 1 to 36 months). The median OS was 26 months. The rates of OS at 12, 24, and 36 months were 80%, 80%, and 40.5%, respectively. The perioperative mortality and morbidity rates were 4.8% and 33.3%, respectively. The 3-year survival rate was 93.8 % for patients treated with a CC 0 or 1 resection, whereas the median OS was 6 months for those treated with a CC 2 or 3 resection (p= 0.007). Age, gender, smoking status, asbestos exposure, pathological type, peritoneal cancer index (PCI), lymph node involvement, ascites, and cancer antigen (CA)-125 were not found to significantly influence the OS in univariate analysis (p> 0.05). A successful CRS plus HIPEC in selected patients with MPM seems to have beneficial effects on OS. In addition, our morbidity and mortality rates are consistent with the current literature.Keywords: Malignant mesothelioma, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Survival, Mortality ÖZET Malign Peritoneal Mezotelyoma Hastalarında Sitoredüktif Cerrahi ve Hipertermik İntraperitoneal Kemoterapi (HIPEC) Etkinliği: Tersiyer Bir Merkez DeneyimiBu çalışmada oldukça nadir görülen bir tümör olan malign peritoneal mezotelyoma olgularında sitoredüksiyon cerrahisi ve hipertermik intraperitoneal kemoterapinin (HIPEC) genel sağkalım (OS), morbidite ve mortalite oranları üzerindeki etkisi araştırıldı. Bu çalışmada Ocak 2012 -Mart 2017 tarihleri arasında malign mezotelyoma tanısı konulan ve akabinde sitoredüksiyon cerrahisi ve HIPEC tedavisi uygulanan 21 olgu retrospektif olarak incelendi. Hastaların ortanca yaşı 60 (18-80) yıl idi. On sekiz hastada (%76.2) asbeste maruz kalma öyküsü vardı. Ortanca takip süresi 17 (1-36) ay olarak bulundu. Ortanca OS süresi 26 aydı. 12, 24 ve 36. aylardaki OS oranları sırasıyla %80, %80 ve %40.5 olarak saptandı. Perioperatif mortalite ve morbidite oranları sırasıyla %4.8 ve %33,3 idi. Sitoredüksiyon skoru (CC) 0 veya 1 olan hastalarda 3 yıllık OS oranı %93.8 iken, CC 2 veya 3 olanlarda ortanca OS 6 ay olarak tespit edildi (p= 0.007). Tek değişkenli analizde yaş, cinsiyet, sigara içme durumu, asbeste maruz kalma, patolojik tip, Peritoneal Kanser İndeksi (PCI) skoru, lenf nodu tutulumu, asit ve kanser antijen (CA)-125'in OS'yi anlamlı derecede etkilemediği bulundu (p> 0.05). Malign peritoneal mezotelyoma olgularında başarılı bir sitoredüksiyon cerrahisi ve HIPEC tedavisi, sağkalım üzerinde olumlu bir etkiye sahiptir. Morbidite ve mortalite oranlarımız literatür ile uyumludur.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Malignant Peritoneal Mesothelioma: A Tertiary Center Experience

Şahin¹

2018

UHOD

View full text Add to dashboard Cite

show abstract

Classical and Minimally Invasive Approaches and Surgical Techniques for Malignant Pleural Effusions

Nistor

Ciuche²,

Bontaș

2020

Thoracic Surgery

View full text Add to dashboard Cite

A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT

S¹,

Okamura

Koyama

et al. 2020

Clin Nucl Med

View full text Add to dashboard Cite

A 62-year-old woman was referred for cough and lower abdominal pain. 18F-FDG PET/CT showed strong uptake not only in the left lung mass and hilar and mediastinal lymph nodes, but also a huge lower abdominal mass. All lesions were initially thought to be multiple metastases because bronchial biopsy of the lung mass showed poorly differentiated adenocarcinoma. However, the abdominal mass was found to be malignant peritoneal mesothelioma after surgical resection. It was difficult to diagnose this case correctly before resection because localized malignant peritoneal mesothelioma is rare.

show abstract

Malignant Peritoneal Mesothelioma Masquerades as Peritoneal Metastasis on 18F-FDG PET/CT Scans; a Rare Diagnosis that Should Not Be Missed

Cited by 4 publications

References 10 publications

The Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Malignant Peritoneal Mesothelioma: A Tertiary Center Experience

The Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Malignant Peritoneal Mesothelioma: A Tertiary Center Experience

Classical and Minimally Invasive Approaches and Surgical Techniques for Malignant Pleural Effusions

A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT

Contact Info

Product

Resources

About